Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. Huuhtanen J, et al. Among authors: yadav b. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585. J Clin Invest. 2022. PMID: 36047494 Free PMC article.
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.
Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K. Pietarinen PO, et al. Among authors: yadav b. Blood Cancer J. 2015 May 1;5(5):e309. doi: 10.1038/bcj.2015.30. Blood Cancer J. 2015. PMID: 25933373 Free PMC article.
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S. Kreutzman A, et al. Among authors: yadav b. Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210. eCollection 2019. Oncoimmunology. 2019. PMID: 31428530 Free PMC article.
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Malani D, et al. Among authors: yadav b. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17. Cancer Discov. 2022. PMID: 34789538 Free PMC article.
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.
Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA. Kuusanmäki H, et al. Among authors: yadav b. Haematologica. 2020 Mar;105(3):708-720. doi: 10.3324/haematol.2018.214882. Epub 2019 Jul 11. Haematologica. 2020. PMID: 31296572 Free PMC article. No abstract available.
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K. Kontro M, et al. Among authors: yadav b. Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8. Leukemia. 2017. PMID: 27499136
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. Karjalainen R, et al. Among authors: yadav b. Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15. Blood. 2017. PMID: 28619982 Free article.
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, Javarappa KK, Porkka K, Wolf M, Aittokallio T, Wennerberg K, Heckman CA, Murumägi A, Kallioniemi O. Malani D, et al. Among authors: yadav b. Leukemia. 2020 Oct;34(10):2780-2784. doi: 10.1038/s41375-020-0978-7. Epub 2020 Jul 17. Leukemia. 2020. PMID: 32678289 No abstract available.
820 results